Chronic Atypical Neuroleptic Treatment

慢性非典型抗精神病药治疗

• 批准号: 6990516
• 负责人: GENE P. SACKETT
• 金额: $ 34.88万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6990516
• 关键词: Macaca nemestrina; animal developmental psychology; antipsychotic agents; behavioral /social science research tag; cognition; dosage; drug adverse effect; drug screening /evaluation; ethology; exploratory behavior; growth /development; juvenile animal; pharmacokinetics; psychopharmacology; risperidone; social behavior

DESCRIPTION (provided by applicant): Atypical neuroleptics such as risperidone and quetiapine are being used frequently in children and adolescents with severe psychopathology. The effects of these agents on normal growth and development are currently unknown. This project will treat 48 normally developing young pigtail monkeys (Macaca nemestrina) with risperidone, quetiapine, or placebo from 13-24 months of age, and will study a four-month post-drug period. Monkeys at one year of age are developmentally similar to children at 4 years of age in physical maturation, motor skills, physiology, and proportion reached in the species lifespan. Twelve males will receive a low dose of risperidone or quetiapine for 4 months, and then 8 in each drug group will be switched to a high dose for 4 months. Twenty-four males will be assigned to the placebo condition. Animals will be tested before, during, and after drug or placebo treatment for (1) social, emotional, exploratory, learning and memory, motor skill, and perceptual behavior; and (2) physical assessments of health, somatic growth, bone mineralization, immune system status, and hormonal function. The study design will permit both between-group and within-individual comparisons to examine drug group differences as well as alterations in individual growth rates caused by the drugs. Since pigtail monkeys demonstrate psychological and somatic development comparable to humans, this project will identify aspects of development in human children that are likely to be affected by chronic treatment with these agents.

描述（由申请人提供）：非典型抗精神病药如利培酮和喹硫平经常用于患有严重精神病理学的儿童和青少年。 这些药物对正常生长和发育的影响目前尚不清楚。 该项目将使用利培酮、喹硫平或安慰剂治疗 48 只正常发育的 13 至 24 个月龄幼年猪尾猴 (Macaca nemestrina)，并研究四个月的用药后时期。 一岁的猴子在身体成熟、运动技能、生理机能和物种寿命所达到的比例方面与四岁的儿童发育相似。 12 名男性将接受低剂量利培酮或喹硫平治疗 4 个月，然后每个药物组中的 8 名男性将改用高剂量治疗 4 个月。 二十四名男性将被分配到安慰剂组。 将在药物或安慰剂治疗之前、期间和之后对动物进行以下测试：（1）社交、情感、探索、学习和记忆、运动技能和知觉行为； (2) 健康、躯体生长、骨矿化、免疫系统状态和激素功能的身体评估。 研究设计将允许进行组间和个体内比较，以检查药物组差异以及药物引起的个体生长率的变化。 由于猪尾猴表现出与人类相当的心理和躯体发育，因此该项目将确定人类儿童的发育方面可能会受到这些药物的长期治疗的影响。